The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Results from the phase III ELEVATE TN trial in patients with treatment-naïve chronic lymphocytic leukemia

Dec 19, 2019

Acalabrutinib is a highly selective Bruton tyrosine kinase inhibitor (BTKi) that has demonstrated durable responses and a favorable safety profile when combined with obinutuzumab in treatment-naïve (TN) chronic lymphocytic leukemia (CLL).

At the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Jeff Sharman, Willamette Valley Cancer Institute and Research Center & US Oncology Network, Eugene, OR, presented results from the multicenter, open-label phase III ELEVATE TN trial of acalabrutinib combined with obinutuzumab (O) vs acalabrutinib alone vs O plus chlorambucil (Clb) in patients with TN CLL.1

Study design

  • Study participants (N= 535) with TN CLL aged ≥ 65 years or < 65 years with coexisting conditions were recruited
  • Patients were stratified according to deletion(17p) status, ECOG status, and geographic region
  • Randomization was 1:1:1 to receive oral acalabrutinib alone (n= 179), or acalabrutinib combined with intravenous O (n= 179), or O plus oral Clb (n= 177; standard frontline chemoimmunotherapy for CLL)
  • The primary endpoint was progression-free survival (PFS) with acalabrutinib + O vs O + Clb
  • Key secondary endpoints included PFS with acalabrutinib vs O + Clb, overall response rate (ORR), overall survival (OS), and safety
  • Crossover from the O + Clb arm to acalabrutinib was allowed after confirmation of progression



  • At a median follow-up of 28.3 months, PFS in the acalabrutinib + O arm (hazard ratio [HR]= 0.10; 95% CI, 0.06–0.17; p< 0.0001) and in the acalabrutinib alone arm (HR= 0.20; 95% CI, 0.13–0.30; p< 0.0001) was not reached (NR) vs 22.6 months for O + Clb
  • Estimated 24-month PFS was 93%, 87%, and 47% for acalabrutinib + O, acalabrutinib alone, and O + Clb, respectively
  • Subgroup analysis showed that PFS improvement for acalabrutinib + O and acalabrutinib alone arms were consistent across all subgroups examined (age, sex, Rai stage, ECOG status, bulky disease, cytogenetic risk group, IGHD mutation status, and karyotype)
  • The study allowed crossover, and 45 patients out of 82 that experienced disease progression in the O + Clb arm crossed over to the acalabrutinib monotherapy arm


  • ORR was 93.9% with acalabrutinib + O (partial response [PR] 81%; complete response [CR] 13%), 85.5% with acalabrutinib monotherapy (PR 85%; CR 1%), and 78.5% in the O + Clb arm (PR 74%; CR 5%). The higher ORR rate of acalabrutinib + O was statistically significant compared to the O + Clb arm (p< 0.0001)


  • Estimated 24-month OS rates were 95%, 95%, and 92% in acalabrutinib + O, acalabrutinib, and O + Clb arms, respectively

Adverse events

  • Serious Adverse Events (SAEs) were reported in 38.8%, 31.8%, and 21.9% of subjects in acalabrutinib + O, acalabrutinib, and O + Clb arms, respectively. The most common SAEs were represented by pneumonia, infusion-related reactions, anemia, neutropenia, and tumor lysis syndrome
  • AEs of clinical interest included:
    • Atrial fibrillation (any grade: acalabrutinib + O, 3.4%; acalabrutinib, 3.9%; O + Clb, 0.6%)
    • Bleeding (any grade: acalabrutinib + O, 42.7%; acalabrutinib, 39.1%; O + Clb, 11.8%)
    • Hypertension (Grade ≥3: acalabrutinib + O, 2.8%; acalabrutinib, 2.2%; O + Clb, 3%)
  • The higher percentage of SAEs and AEs observed in the acalabrutinib arms vs the O + Clb arm may be due to differences in the length of treatment period. The median exposure was 27.7 months for acalabrutinib with or without O (range, 2.3–40.3 months and 0.3–40.2 months, respectively) and only 5.6 months (range, 0.9–7.4 months) for O + Clb


  • A significant PFS improvement was observed in the acalabrutinib arms in comparison with the O + Clb arm, and this PFS improvement was consistent across all subgroups examined
  • ORR was higher in both acalabrutinib arms vs O + Clb, with CR rates higher with acalabrutinib + O vs O + Clb
  • Acalabrutinib showed tolerable safety in patients with TN CLL, but differences in the length of treatment period could be a limitation of the study

Expert Opinion

  1. Sharman J.P. et al. ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Oral Abstract #31. 2019 Dec 7. 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, FL